This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Augmedix Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Manny Krakaris

İcra Kurulu Başkanı

US$919.1k

Toplam tazminat

CEO maaş yüzdesi	49.9%
CEO görev süresi	6yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	4.8yrs
Yönetim Kurulu ortalama görev süresi	3yrs

Son yönetim güncellemeleri

Recent updates

Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Jun 19

Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

May 21

Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Apr 25

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Mar 24

Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Nov 09

Augmedix reports Q2 results

Aug 08

Augmedix: A Splendid Long-Term Investing Opportunity

Jan 21

CEO Tazminat Analizi

Manny Krakaris'un ücretlendirmesi Augmedix'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$24m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$919k	US$459k	-US$19m
Sep 30 2023	n/a	n/a	-US$20m
Jun 30 2023	n/a	n/a	-US$21m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$1m	US$450k	-US$24m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$21m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$2m	US$400k	-US$17m
Sep 30 2021	n/a	n/a	-US$16m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$16m
Dec 31 2020	US$634k	US$296k	-US$16m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$18m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$511k	US$350k	-US$18m

Tazminat ve Piyasa: Manny 'nin toplam tazminatı ($USD 919.10K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 647.72K ).

Tazminat ve Kazançlar: Manny 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Manny Krakaris (65 yo)

6yrs

Görev süresi

US$919,099

Tazminat

Mr. Emmanuel Krakaris, also known as Manny, is President, Secretary and Director of Augmedix, Inc. since October 2018 and is its Chief Executive Officer since October 2018. Mr. Krakaris served as the Chie...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Emmanuel Krakaris	President	6yrs	US$919.10k	0.13% $ 152.2k
Ian Shakil	Founder	no data	US$818.06k	0.020% $ 23.6k
Sandra Breber	Chief Operating Officer	5.6yrs	US$651.09k	0.041% $ 47.7k
Paul Ginocchio	Chief Financial Officer	4.3yrs	Veri yok	0.27% $ 319.1k
Saurav Chatterjee	Chief Technology Officer	3.9yrs	US$633.35k	0.012% $ 13.7k
Todd Holvick	Head of Legal & Compliance	no data	Veri yok	Veri yok
Lia Wallick	Head of People	5.4yrs	Veri yok	Veri yok
Davin Lundquist	Chief Medical Officer	4.8yrs	Veri yok	Veri yok
Jonathan Hawkins	Chief Revenue Officer	5.5yrs	US$440.01k	0.012% $ 13.7k
Tomer Levy	Senior Vice President of Engineering	less than a year	Veri yok	Veri yok
Alex Stinard	Chief Clinical AI Officer	less than a year	Veri yok	Veri yok

4.8yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: AUGX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Emmanuel Krakaris	President	6yrs	US$919.10k	0.13% $ 152.2k
Ian Shakil	Founder	11.5yrs	US$818.06k	0.020% $ 23.6k
William Febbo	Independent Director	2.6yrs	US$181.29k	0.33% $ 382.1k
Roderick O'Reilly	Independent Non-Executive Chairman of the Board	1.6yrs	US$548.26k	0.044% $ 50.8k
Jason Krikorian	Independent Director	7.4yrs	US$200.00k	0.15% $ 174.4k
Robert Faulkner	Independent Director	1.5yrs	US$128.44k	0.084% $ 97.4k
Laurie McGraw	Lead Independent Director	2.6yrs	US$210.64k	0.15% $ 174.4k
Margie Traylor	Independent Director	3.4yrs	US$190.64k	0.25% $ 291.7k

3.0yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AUGX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3 yıldır).

This company has been acquired

Augmedix Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Augmedix Appoints Alex Stinard as Chief Clinical AI Officer

Founder notifies of intention to sell stock

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

High number of new directors

Augmedix, Inc., Annual General Meeting, Jul 13, 2023

Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product Development

Recent updates

Augmedix's Stock Ceases Trading and to be Delisted from the Nasdaq Stock Market

Commure, Inc. completed the acquisition of Augmedix, Inc. (NasdaqCM:AUGX) from a group of shareholders.

Second quarter 2024 earnings: EPS misses analyst expectations

Augmedix, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million.

Commure, Inc. entered into an agreement and plan of merger to acquire Augmedix, Inc. (NasdaqCM:AUGX) from Redmile Group, LLC, Hinsight-Augx Holdings, Llc and others for approximately $120 million.

Augmedix, Inc. (NASDAQ:AUGX) Stock's 38% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Augmedix, Inc. Reiterates Earnings Guidance for the Second Quarter and Full Year of 2024

Augmedix Appoints Alex Stinard as Chief Clinical AI Officer

Is Augmedix, Inc. (NASDAQ:AUGX) Trading At A 40% Discount?

Consensus revenue estimates fall by 13%

First quarter 2024 earnings: EPS exceeds analyst expectations

Augmedix, Inc. Provides Revenue Guidance for the Year 2024

Price target increased by 12% to US$6.83

Now 26% overvalued

Augmedix, Inc. to Report Q1, 2024 Results on May 13, 2024

Augmedix, Inc. (NASDAQ:AUGX) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Augmedix Launches Industry's First Fully-Automated, GenAI-Powered, Medical Documentation Product for Emergency Departments

Founder notifies of intention to sell stock

Consensus EPS estimates fall by 15%

Augmedix: Secular AI Tailwinds, But Still Unattractive Risk-Reward

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Augmedix Announces New Positive Data and Enhancements to Its Ambient AI Product, Augmedix Go

Augmedix, Inc. to Report Q4, 2023 Results on Mar 18, 2024

Now 21% undervalued after recent price drop

Augmedix Names Tomer Levy as New Senior Vice President of Engineering

Now 22% overvalued after recent price rise

Augmedix, Inc. Revises Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Augmedix, Inc. has filed a Follow-on Equity Offering.

Price target increased by 7.0% to US$7.63

Augmedix, Inc. (NASDAQ:AUGX) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Augmedix, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target increased by 12% to US$7.13

High number of new directors

Augmedix Announces New AI Medical Documentation Product, Augmedix Go, a Clinician Controlled Mobile App

Augmedix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Augmedix, Inc., Annual General Meeting, Jul 13, 2023

Augmedix Establishes AI Advisory Council to Guide the Company's Continued Development of High Standard, Responsible Product Development

Joseph W. Marks to Resign from the Augmedix's Board of Directors Effective on the Date of 2023 Annual Meeting of Stockholders

Augmedix, Inc. Provides Revenue Guidance for the Year 2023

Augmedix, Inc. to Report Q1, 2023 Results on May 12, 2023

Augmedix, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Augmedix, Inc. announced delayed 10-Q filing

Augmedix, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Augmedix Launches New Service, Augmedix Prep, to Significantly Reduce Physician Chart Prep Burden

Augmedix, Inc. Announces Resignation of Gerard Van Hamel Platerink as Director

Augmedix reports Q2 results

Augmedix - Trio Health - CIIC Announce the Launch of an Innovative Platform

Augmedix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Augmedix, Inc. to Report Q1, 2022 Results on May 09, 2022

Augmedix, Inc. Names William Febbo as New Member to its Board of Directors

Augmedix: A Splendid Long-Term Investing Opportunity

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş